IRTC:NSD-iRhythm Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 105.99

Change

+1.21 (+1.15)%

Market Cap

USD 3.28B

Volume

0.20M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.88 (+1.24%)

USD 23.46B
PODD Insulet Corporation

+1.33 (+0.51%)

USD 17.22B
MASI Masimo Corporation

+1.11 (+0.68%)

USD 7.80B
BRKR Bruker Corporation

+0.10 (+0.26%)

USD 5.53B
PRCT Procept Biorobotics Corp

-0.07 (-0.13%)

USD 2.85B
TMDX TransMedics Group Inc

-0.68 (-0.72%)

USD 2.73B
QDEL Quidel Corporation

+0.31 (+1.12%)

USD 2.42B
LIVN LivaNova PLC

N/A

USD 1.95B
NVCR Novocure Ltd

-0.05 (-0.27%)

USD 1.81B
UFPT UFP Technologies Inc

-0.09 (-0.04%)

USD 1.62B

ETFs Containing IRTC

EDOC:LSE Global X Telemedicine & D.. 4.35 % 0.00 %

+0.01 (+0%)

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 4.35 % 0.00 %

N/A

USD 0.33M
FDHT:XETRA 2.58 % 0.00 %

N/A

N/A
KOMP SPDR Kensho New Economies.. 0.00 % 0.00 %

+0.38 (+0%)

USD 1.89B
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.54% 85% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.54% 85% B 89% A-
Trailing 12 Months  
Capital Gain -5.29% 68% D+ 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.29% 68% D+ 47% F
Trailing 5 Years  
Capital Gain 5.52% 79% B- 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.52% 79% B- 40% F
Average Annual (5 Year Horizon)  
Capital Gain -1.40% 46% F 37% F
Dividend Return -1.40% 46% F 33% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.64% 52% F 31% F
Risk Adjusted Return -2.35% 47% F 35% F
Market Capitalization 3.28B 96% N/A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector